Search - tctmd.com

Displaying 801 - 820 of 970

Sort: Relevancy | Date

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Presenter: Kurt Huber

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

Presentation TCT 2013

Platelet Function and Genetic Testing are Currently Worthless

Presenter: Daniel Simon

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Presentation TCT 2013

Genetic Testing is of Clear Clinical Utility in Selected Patients

Presenter: Jessica Mega

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Presenter: Freek Verheugt

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Presenter: Pascal Vranckx

October 31, 2013

Presentation TCT 2013

Critical Appraisal and Clinical Implications(3)

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Presenter: Philippe Gabriel Steg

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Presentation TCT 2013

BRIDGE Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

A Patient with a Recent Stent Who is Bleeding

Presenter: Peter Wenaweser

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

Advertisement

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Platelet Function and Genetic Testing are Currently Worthless

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Mortality Trumps All: Ticagrelor for (Nearly) All!

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Genetic Testing is of Clear Clinical Utility in Selected Patients

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Critical Appraisal and Clinical Implications(3)

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

BRIDGE Recap

A Patient with a Recent Stent Who is Bleeding

OPTIMIZE: 3-Month DAPT Safe with ZES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content